BREAST CANCER RISK ASSESSMENT IN BENIGN BREAST DISEASE

良性乳腺癌的乳腺癌风险评估

• 批准号: 3189584
• 负责人: L. JOSEPH MELTON
• 金额: $ 17.66万
• 依托单位: MAYO CLINIC ROCHESTER
• 依托单位国家: 美国
• 财政年份: 1987
• 资助国家: 美国
• 起止时间: 1987-09-30 至 1990-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/3189584
• 关键词: DNA; breast neoplasms; cancer risk; flow cytometry; histopathology; human subject; immunochemistry; mammary disorder

This proposal utilizes the unique resources of Mayo Clinic and the Rochester Epidemiology Program Project (REPP) to conduct a retrospective incidence cohort study to assess breast cancer risk among women with benign breast disease. By integrating the histopathologic evaluation capabilities of Mayo Clinic and the population-based epidemiologic data provided by the REPP, this research will provide a detailed assessment of the risk of breast cancer associated with specific histologically defined subcategories of proliferative benign breast disease. The study pathologist will collaborate with Dr. Page to ensure that the Page-Dupont criteria are applied to the breast tissue pathologic slides. Breast tissue from an estimated (9,000) women in the Olmsted County community and at Mayo Clinic from 1/1/67- 1/1/83 will be evaluated histopathologically with these criteria, and this retrospective incidence cohort will be followed for occurrence of breast cancer to 1/1/88. Using breast cancer cases and a matched control group from this cohort, a nested biopsy from medical records of these patients. In addition, DNA flow cytometry and immunohistochemistry will be conducted on benign breast disease tissue from cases and controls. The combined clinical, epidemiologic, flow cytometric, and histopathologic data will be used to evaluate the interaction between these factors and breast cancer risk. Previous REPP research concerned with the relationship between benign breast lesions and subsequent breast cancer affirms the ability of this data source to identify the relevant study population. Ongoing participation in the DES- breast cancer studies verifies the ability to determine the appropriate clinical and epidemiologic parameters and to provide nearly 100% follow-up for breast cancer occurrence to 1/1/88 in this (9,000) member benign breast disease incidence cohort. More than 300 cases of breast cancer are anticipated in this cohort which should provide adequate power to detect clinically and statistically important relationships of interest. Comparisons between the Olmsted County cohort and the non-Olmsted County Mayo Clinic referral cohort will provide a unique opportunity to determine the influence of referral bias on the epidemiology of benign breast disease. This study will, therefore, assess the predictive validity of the Page-Dupont criteria and determine if additional clinical, epidemiologic, flow cytometric, or histopathologic factors improve the precision of risk assessment.

这项建议利用了梅奥诊所的独特资源和 罗切斯特流行病学计划项目(REPP)进行 用于评估乳腺癌风险的回溯性发病队列研究 在患有良性乳腺疾病的女性中。通过集成 梅奥诊所的组织病理学评价能力及其临床意义 REPP提供的基于人口的流行病学数据，这 研究将提供对乳房风险的详细评估 与特定组织学定义相关的癌症 增生性良性乳腺疾病的亚类。这项研究 病理学家将与佩奇博士合作，确保 PAGE-Dupont标准应用于乳腺组织病理学 幻灯片。估计(9000)名妇女的乳房组织 奥姆斯特德县社区和梅奥诊所从67年1月1日起- 1/1/83将根据这些标准进行组织病理学评估， 这个回溯性的发病队列将被用于 乳腺癌发病率降至1/1/88。使用乳腺癌病例 和来自这个队列的匹配的对照组，套式活检 从这些病人的医疗记录中。此外，DNA流 将对良性病变进行细胞学和免疫组织化学检查 病例和对照的乳腺疾病组织。合并后的 临床、流行病学、流式细胞术和组织病理学资料 将被用来评估这些因素和 乳腺癌风险。以前的REPP研究关注的是 乳腺良性病变与继发性乳腺病变的关系 巨蟹座肯定了这一数据源识别 相关研究人群。持续参与DES- 乳腺癌研究证实有能力确定 适当的临床和流行病学参数，并提供 乳腺癌发生的近100%随访率为1/1/88 本(9,000)名成员良性乳腺疾病发病队列。更多 在这一队列中，预计有300多例乳腺癌病例。 它应该提供足够的能量来检测临床和 统计上重要的利益关系。比较 在奥姆斯特德县队列和非奥姆斯特德县之间 梅奥诊所的转诊队列将提供一个独特的机会 确定转诊偏向对慢性病流行病学的影响 良性乳房疾病。因此，这项研究将评估 Page-Dupont标准的预测效度，并确定 其他临床、流行病学、流式细胞术或 组织病理学因素提高了风险评估的精确度。